Journal of Clinical Oncology
Articles in this Issue
The impact of transportation barriers on rural cancer patients: A systematic review.
e13743 Background: Transportation barriers significantly limit rural cancer patients’ access to potentially life-saving treatments compared to their urban...
Randomized dose evaluation of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma: Results from RELATIVITY-020.
9526 Background: NIVO + RELA is approved at 480 mg NIVO + 160 mg RELA Q4W (480/160) dosing for treatment of advanced melanoma based on RELATIVITY-047. A h...
A novel agent, para-toluenesulfonamide, for the management of malignant pleural effusions.
e15139 Background: Malignant pleural effusion (MPE) is the lethal consequence of various human cancers. No effective agents are currently available to cur...
RETRACTED: Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.
8516 Background: Recent retrospective studies across 10 cancer types suggest increased efficacy of Early rather than Late...
Melanoma and pregnant women: A systematic review and meta-analysis.
e21579 Background: Pregnancy-associated melanoma (PAM) is melanoma that can develop up to one year post pregnancy. There is no solid evidence on how pregn...
Assessment of survival and role of chemotherapy in patients with adrenocortical carcinoma: Insights from SEER Database (2000–2021).
e16610 Background: Adrenocortical carcinoma (ACC) is a rare malignancy with an incidence of 1-2 per million per year. The optimal treatment remains unclea...
Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial.
4057 Background: Neoadjuvant chemoradiotherapy followed by esophagectomy is the standard of care for locally advanced esophageal squamous cell carcinoma (...
Racial disparities in metastatic castration-resistant prostate cancer clinical trials between 2005 and 2021.
e17061 Background: Despite significant racial and ethnic disparities in prostate cancer incidence and mortality in the United States and worldwide, clinic...
A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from non-adenoid cystic cohort.
6106 Background: Treatment options for pts with R/M SGC are limited. Responses to chemotherapy (CT) are low with high toxi...
Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
e17076 Background: PANTHER is a multicenter prospective trial of Black and White cohorts of metastatic castration resistant prostate cancer (mCRPC) patien...
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in patients with HPV-positive oropharyngeal cancer (ReACT 1.0).
6009 Background: Human papillomavirus-positive oropharyngeal cancer (HPV+ OPC) has favorable outcomes with platinum-based concurrent chemoradiation (CRT),...
Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.
4046 Background: For unresectable locally advanced or metastatic HER2-negative gastric cancer (GC), the combination of chemotherapy with immunotherapy, sp...
First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC).
4518 Background: Standard of care for MIBC is radical cystectomy (RC) with neoadjuvant chemotherapy (CT), but ~50% of patients (pts) are ineligible for/re...
Investigation of liver-specific gene expression signatures in prostate cancers prior to liver metastases.
e17083 Background: It has been recognized that as a prostate cancer (PCa) metastasizes to bone, it begins to express bone-specific proteins such as osteop...
Optimizing chemotherapy decisions in low-resource settings with deep learning: A novel approach for unresectable NSCLC.
e13668 Background: Even though chemotherapy offers less survival advantages in the era of targeted therapy and immunotherapy, nevertheless, it remains the...
Predictive imaging of the immunotherapy and radioimmunotherapy response by immunoPET via a new target (CD103) and innovative protein formats in preclinical NSCLC.
2559 Background: Immune checkpoint immunotherapies (ICI) have transformed cancer treatment, but patients have varied responses and potential risks of auto...
Pilot study of an enhanced telehealth program for patients with prostate cancer.
1647 Background: The time required for cancer treatment is considerable. Telehealth (TH) with home monitoring can minimize travel burden but patients’ per...
Tumour microbiome and immune dysregulation in early-onset colorectal cancer.
3545 Background: Early-onset colorectal cancer (EOCRC) in patients under 50 years is increasing incidence in many countries worldwide, including New Zeala...
A phase I study of a pooled synthetic long peptide mutant KRAS vaccine in patients with pancreatic cystic neoplasms at risk for developing pancreatic cancer.
TPS2699 Background: Mutant KRAS (mKRAS) is an oncogenic driver expressed in > 90% of patients with pancreatic ductal adenocarcinoma (PDAC) and the majo...
Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I <sub>R</sub> IVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).
10024 Background: Event-free survival for patients in the highest risk groups of rhabdomyosarcoma (RMS) remains poor. The COG ARST0431 study showed that d...
Real-world analysis of effectiveness in unresectable hepatocellular carcinoma patients treated with camrelizumab-based regimens.
e16204 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with limited therapeutic options for advanced stages. Ca...
Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies.
6505 Background: Lisaftoclax (LISA), an investigational, orally active small molecule BCL-2 inhibitor, has shown enhanced treatment responses when combine...
Hypertension and renal cancer-related mortality patterns in the United States from 1999 to 2020.
e16517 Background: According to the American Cancer Society, approximately 14,000 individuals died from kidney cancer in 2024. Hypertension (HTN) is a wel...
Real-world treatment landscape in patients with squamous cell carcinoma of the anal canal (SCAC) in the United States.
e15503 Background: SCAC is a rare malignancy, representing < 1% of all cancer diagnoses annually, with suboptimal survival outcomes in advanced or meta...
Chemotherapy-induced changes in blood indices among chronic dialysis patients: A nationwide study.
e24122 Background: End-stage renal disease (ESRD) patients often experience compromised bodily function, erythropoietin deficiency, and altered bone marro...